This company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsBiotest (BIO3D) 주식 개요Develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. 자세히 보기BIO3D 펀더멘털 분석스노우플레이크 점수가치 평가2/6미래 성장4/6과거 실적0/6재무 건전성1/6배당0/6강점수익은 매년 94.11% 증가할 것으로 예상됩니다.위험 분석주식은 유동성이 매우 낮습니다cash runway 경력이 1년 미만입니다.모든 위험 점검 보기BIO3D Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€32.0059.5% 저평가 내재 할인율Growth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-54m895m2016201920222025202620282031Revenue €895.3mEarnings €162.7mAdvancedSet Fair ValueView all narrativesBiotest Aktiengesellschaft 경쟁사GenusSymbol: LSE:GNSMarket cap: UK£1.7bOxford BiomedicaSymbol: LSE:OXBMarket cap: UK£747.3mBioventixSymbol: AIM:BVXPMarket cap: UK£87.5mTissue Regenix GroupSymbol: AIM:TRXMarket cap: UK£5.2m가격 이력 및 성과Biotest 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가€32.0052주 최고가€35.5052주 최저가€32.00베타0.291개월 변동0%3개월 변동n/a1년 변동n/a3년 변동60.00%5년 변동31.96%IPO 이후 변동118.18%최근 뉴스 및 업데이트공시 • May 23Biotest Aktiengesellschaft announces Annual dividend, payable on July 07, 2025Biotest Aktiengesellschaft announced Annual dividend of EUR 0.0400 per share payable on July 07, 2025, ex-date on July 03, 2025 and record date on July 04, 2025.공시 • May 22Biotest Aktiengesellschaft, Annual General Meeting, Jul 02, 2025Biotest Aktiengesellschaft, Annual General Meeting, Jul 02, 2025, at 10:30 W. Europe Standard Time.공시 • Apr 02Grifols Biotest Holdings GmbH, proposed to acquire remaining 28.31% stake in Biotest Aktiengesellschaft (XTRA:BIO3) from shareholders for approximately €340 million.Grifols Biotest Holdings GmbH, proposed to acquire remaining 28.31% stake in Biotest Aktiengesellschaft (XTRA:BIO3) from shareholders for approximately €340 million on March 31, 2025. The Management Board and the Supervisory Board will carefully review the offer document for the public delisting acquisition offer and issue a joint reasoned statement in accordance with Section 27 of the German Securities Acquisition and Takeover Act. The delisting agreement contains provisions that Grifols, S.A. intends to support Biotest AG in an economically reasonable manner. After the revocation of the stock exchange admission becomes effective, the shares of Biotest AG will no longer be admitted to trading on a domestic regulated market or a comparable market abroad. According to the provisions of the delisting agreement, Grifols Biotest Holdings GmbH, a 100% subsidiary of Grifols, S.A., will make an unconditional public delisting acquisition offer to the shareholders of Biotest AG to acquire all ordinary and preference shares of Biotest AG that are not already held by Grifols Biotest Holdings GmbH, in exchange for a cash consideration of €43.00 per Biotest ordinary share and €30.00 per Biotest preference share, subject to adjustments due to legal provisions. The terms and conditions of the delisting offer will be communicated in the offer document ("Offer Document") to be prepared by Grifols and to be examined by the German federal financial supervisory. Banco Santander, S.A. acted as a financial advisor to Biotest Aktiengesellschaft.공시 • Mar 18+ 1 more updateBiotest Aktiengesellschaft to Report Q3, 2025 Results on Nov 10, 2025Biotest Aktiengesellschaft announced that they will report Q3, 2025 results on Nov 10, 2025공시 • Mar 07Martin Möller to Leave as Chief Financial Officer of Biotest AG on 15 March 2025The Board of Management of Biotest AG announced that Chief Financial Officer Martin Möller will terminate his position as CFO as planned at the end of his contract expires on 15 March 2025. The Supervisory Board has already initiated the search for a suitable successor and aims to fill the position in the near future. Martin Möller will continue to support Biotest AG in an advisory capacity beyond the end of his contract.공시 • Jan 09Important milestone for Biotest: Biologics License Application for Fibrinogen submitted to the US Food and Drug Administration (FDA)Biotest AG announced that the Biologics License Application (BLA) for Biotest’s Fibrinogen has been submitted to the US Food and Drug Administration. Fibrinogen is the second product developed and manufactured by Biotest in Dreieich, Germany, for which a BLA has been submitted to the FDA. The new application covers both supplementation in patients with acquired fibrinogen deficiency and treatment and prophylaxis of acute bleeding episodes in all patients with congenital fibrinogen deficiency. The application is now under evaluation by the FDA, with a decision anticipated by the end of 2025. This submission follows Biotest’s earlier application for marketing authorization in selected European markets filed in October 2024. In many regions of the world, the use of cryoprecipitate or fresh frozen plasma as a fibrinogen substitute is the standard of care for the management of major surgical bleeding. However, these treatments contain not only fibrinogen, but also additional proteins and components that may exhibit undesired effects for the patient. In addition, they are not subject to the same rigorous pathogen safety protocols as Fibrinogen. Fibrinogen also offers the significant advantages of being readily available and allowing for faster administration, ensuring timely and targeted treatment.더 많은 업데이트 보기Recent updates공시 • May 23Biotest Aktiengesellschaft announces Annual dividend, payable on July 07, 2025Biotest Aktiengesellschaft announced Annual dividend of EUR 0.0400 per share payable on July 07, 2025, ex-date on July 03, 2025 and record date on July 04, 2025.공시 • May 22Biotest Aktiengesellschaft, Annual General Meeting, Jul 02, 2025Biotest Aktiengesellschaft, Annual General Meeting, Jul 02, 2025, at 10:30 W. Europe Standard Time.공시 • Apr 02Grifols Biotest Holdings GmbH, proposed to acquire remaining 28.31% stake in Biotest Aktiengesellschaft (XTRA:BIO3) from shareholders for approximately €340 million.Grifols Biotest Holdings GmbH, proposed to acquire remaining 28.31% stake in Biotest Aktiengesellschaft (XTRA:BIO3) from shareholders for approximately €340 million on March 31, 2025. The Management Board and the Supervisory Board will carefully review the offer document for the public delisting acquisition offer and issue a joint reasoned statement in accordance with Section 27 of the German Securities Acquisition and Takeover Act. The delisting agreement contains provisions that Grifols, S.A. intends to support Biotest AG in an economically reasonable manner. After the revocation of the stock exchange admission becomes effective, the shares of Biotest AG will no longer be admitted to trading on a domestic regulated market or a comparable market abroad. According to the provisions of the delisting agreement, Grifols Biotest Holdings GmbH, a 100% subsidiary of Grifols, S.A., will make an unconditional public delisting acquisition offer to the shareholders of Biotest AG to acquire all ordinary and preference shares of Biotest AG that are not already held by Grifols Biotest Holdings GmbH, in exchange for a cash consideration of €43.00 per Biotest ordinary share and €30.00 per Biotest preference share, subject to adjustments due to legal provisions. The terms and conditions of the delisting offer will be communicated in the offer document ("Offer Document") to be prepared by Grifols and to be examined by the German federal financial supervisory. Banco Santander, S.A. acted as a financial advisor to Biotest Aktiengesellschaft.공시 • Mar 18+ 1 more updateBiotest Aktiengesellschaft to Report Q3, 2025 Results on Nov 10, 2025Biotest Aktiengesellschaft announced that they will report Q3, 2025 results on Nov 10, 2025공시 • Mar 07Martin Möller to Leave as Chief Financial Officer of Biotest AG on 15 March 2025The Board of Management of Biotest AG announced that Chief Financial Officer Martin Möller will terminate his position as CFO as planned at the end of his contract expires on 15 March 2025. The Supervisory Board has already initiated the search for a suitable successor and aims to fill the position in the near future. Martin Möller will continue to support Biotest AG in an advisory capacity beyond the end of his contract.공시 • Jan 09Important milestone for Biotest: Biologics License Application for Fibrinogen submitted to the US Food and Drug Administration (FDA)Biotest AG announced that the Biologics License Application (BLA) for Biotest’s Fibrinogen has been submitted to the US Food and Drug Administration. Fibrinogen is the second product developed and manufactured by Biotest in Dreieich, Germany, for which a BLA has been submitted to the FDA. The new application covers both supplementation in patients with acquired fibrinogen deficiency and treatment and prophylaxis of acute bleeding episodes in all patients with congenital fibrinogen deficiency. The application is now under evaluation by the FDA, with a decision anticipated by the end of 2025. This submission follows Biotest’s earlier application for marketing authorization in selected European markets filed in October 2024. In many regions of the world, the use of cryoprecipitate or fresh frozen plasma as a fibrinogen substitute is the standard of care for the management of major surgical bleeding. However, these treatments contain not only fibrinogen, but also additional proteins and components that may exhibit undesired effects for the patient. In addition, they are not subject to the same rigorous pathogen safety protocols as Fibrinogen. Fibrinogen also offers the significant advantages of being readily available and allowing for faster administration, ensuring timely and targeted treatment.공시 • Nov 15Biotest Aktiengesellschaft to Report Fiscal Year 2024 Results on Mar 28, 2025Biotest Aktiengesellschaft announced that they will report fiscal year 2024 results on Mar 28, 2025공시 • Jul 29Biotest Aktiengesellschaft to Report Q2, 2024 Results on Aug 06, 2024Biotest Aktiengesellschaft announced that they will report Q2, 2024 results on Aug 06, 2024공시 • Jun 18Biotest Receives FDA Approval for Innovative Yimmugo Immunoglobulin to Treat Primary ImmunodeficienciesGrifols announced that Biotest, a Grifols Group company, has received approval from the United States Food and Drug Administration (FDA) for Yimmugo®, an innovative intravenous immunoglobulin (Ig) therapeutic, to treat primary immunodeficiencies (PID). Yimmugo, developed by Biotest, adds to Grifols’ strong franchise of industry-leading intravenous and subcutaneous Ig treatments at a time of growing demand for plasma-derived medicines to treat immunodeficiencies, in which a part of the body’s immune system is missing or does not function properly, and other medical conditions. The first U.S.-approved medicine in Biotest’s portfolio, Yimmugo is produced using a state-of-the-art process at Biotest’s new FDA-certified “Next Level” production facility in Dreieich, Germany, which is already approved for production and marketing in Europe. The launch of Yimmugo in the U.S. in the second part of 2024 follows its successful introduction in Europe at the end of 2022 and is poised to add to Grifols' future revenue growth and profitability. Yimmugo is the first of a threesome of Biotest plasma proteins on the horizon destined for markets including the U.S. The other two, both in late-stage development, are a fibrinogen concentrate (FC) to treat acquired fibrinogen deficiency – it would be the first FC approved for this indication in the U.S. – and trimodulin, a polyvalent Ig to treat community-acquired pneumonia (CAP) or severe community-acquired pneumonia (sCAP). The strategic acquisition of Biotest and the integration of its specialized resources has significantly accelerated Grifols innovation, deepened its product pipeline and furthered its industry leadership. Yimmugo is a newly developed polyvalent immunoglobulin G preparation from human blood plasma for intravenous administration (IVIg). The sugar-free ready-to-use solution is approved in the US for substitution therapy in primary antibody deficiency syndromes. Yimmugo is the first approved product from the new Biotest Next Level production facility. The modern production process stands for the highest product quality and an extremely responsible use of resources. Important Safety Information: Thrombosis may occur with immune globulin intravenous (IGIV) products, including YIMMUGO. Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur with the administration of IGIV products in predisposed patients. Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. YIMMUGO does not contain sucrose. For patients at risk of thrombosis, renal dysfunction or renal failure, administer YIMMUGO at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.공시 • Mar 29Biotest Aktiengesellschaft, Annual General Meeting, May 07, 2024Biotest Aktiengesellschaft, Annual General Meeting, May 07, 2024, at 10:30 Central European Standard Time. Location: Alte Oper Frankfurt, Mozart Saal, Opernplatz, Franfurt Am Main Germany Agenda: To consider the adopted annual financial statements of Biotest AG and the approved consolidated financial statements as at 31 December 2023; to consider the Resolution on the discharge of the members of the Management Board for the financial year 2023; to consider Resolution on the discharge of the members of the Supervisory Board for the financial year 2023; to consider the Election of the auditor for the financial year 2024; and to consider the other business matters.공시 • Jan 23+ 2 more updatesBiotest Aktiengesellschaft to Report First Half, 2024 Results on Jul 30, 2024Biotest Aktiengesellschaft announced that they will report first half, 2024 results on Jul 30, 2024공시 • Nov 03Biotest Aktiengesellschaft to Report Fiscal Year 2023 Results on Mar 28, 2024Biotest Aktiengesellschaft announced that they will report fiscal year 2023 results on Mar 28, 2024공시 • Oct 07Biotest Aktiengesellschaft Raises Earnings Guidance for the Year 2023Biotest Aktiengesellschaft raised earnings guidance for the year 2023. Biotest AG had forecasted in April 2023 an EBIT that may possibly exceed EUR 100 million. Based on current information, the Executive Board expects EBIT for fiscal 2023 to be in the order of EUR 130 - 170 million. The Executive Board continues to aim for a mid-single-digit percentage increase in revenue for the 2023 financial year compared to 2022, excluding revenue from the technology transfer and licensing agreement.공시 • Oct 06Biotest AG Appoints Peter Janssen as Chairman of the Management Board, Effective from January 1, 2024Biotest AG at its meeting held on October 5, 2023 appointed Mr. Peter Janssen (57) as Chairman of the Management Board of Biotest AG with effect from 1 January 2024. He will take over the chairmanship of the Board of Management from Dr Michael Ramroth (62), who held this position for three and a half years and is retiring as planned for reasons of age. Peter Janssen has been a member of the Management Board of Biotest AG since 2022 and heads the Commercial and Industrial Operations divisions. Previously, he was Executive VP of Prothya Netherlands and CEO of Prothya Belgium. Mr. Janssen also worked for Pfizer for 14 years and for its animal health spin-off Zoetis for 5 years. Peter Janssen started his career as an assistant professor at the University of Leuven in Belgium, was a reserve officer in the Belgian Air Force and worked in the semiconductor division of the industrial gas company Air Products in Pennsylvania, USA. He holds a Master of Science (Dipl. Ing.) in Electromechanics, a Master in Business Administration and a Management Diploma from INSEAD in France. In addition to Peter Janssen as Chairman of the Management Board, the Management Board of Biotest AG will continue to include Ainhoa Mendizabal Zubiaga as CFO and Dr. Jörg Schüttrumpf as CSO.공시 • Sep 13Biotest Treats First Patient with Severe Community- Acquired Pneumonia in Phase III Trial with TrimodulinBiotest announced that the first patient with sCAP has been treated in the phase III ESsCAPE trial in an intensive care unit. This multinational phase III clinical trial is expected to enrol approximately 590 adult patients with severe Community Acquired Pneumonia (sCAP). The ESsCAPE trial will be conducted in up to 20 countries worldwide and patients will receive either trimodulin or placebo as add-on therapy to standard of care. Severe CAP is a life-threatening condition. Patients must be admitted to an intensive care unit (ICU) and often receive oxygen through invasive mechanical ventilation (IMV). These patients often develop additional critical illnesses such as sepsis, septic shock, and multiple organ dysfunction or failure. Despite existing treatment options, mortality in these patients remains high. The clinical concept of this prospective, double-blind, placebo-controlled phase III trial, was developed based on the promising results of the previous phase II clinical trial (CIGMA) in 160 sCAP patients requiring IMV. In the CIGMA trial a subgroup of patients with evidence of severe inflammation showed an encouraging reduction in the mortality rate when treated with trimodulin. Biotest's development product trimodulin is a globally unique, innovative polyvalent IgM, IgA, IgG antibody composition, purified from human plasma. In addition to clinical development for sCAP, trimodulin is also currently in development for the treatment of COVID-19. Biotest's development products trimodulin is an innovative polyvalent antibody composition, purified from human Plasma. In comparison to standard IgG preparations (IVIG), trimodulin contains relevant amounts of IgM and IgA in addition to IgG. Trimodulin is currently in clinical development for the treatment of patients with severe community-acquired pneumonia (sCAP) and for patients with moderate or severe COVID-19. Research so far has shown that trimodulin could intervene with a number of mechanisms involved in pathological processes that would otherwise lead to respiratory failure, sepsis, multi-organ failure and finally to death of the patient. Due to the large variety of polyvalent antibodies present in trimodulin, the impaired immune system is supported in various ways. The antibodies bind to various types of pathogens including viruses and bacteria as well as their toxins and support their clearance by the immune system. Particularly the IgM component in trimodulin can reduce dysregulated immune responses, preventing the immune system to attack host tissues, in this case, the lung. In this way, trimodulin may prevent progression of disease, including the need for invasive mechanical ventilation and other intensive care procedures, and finally death. Severe community acquired pneumonia (sCAP) is usually defined as pneumonia acquired outside the hospital that requires intensive medical care. mortality of sCAP patients admitted to the intensive care unit is high and has not improved much in recent years.공시 • Sep 08Biotest AG Announces US Food and Drug Administration Accepts Marketing Authorization Application for Immunoglobulin YimmugoBiotest AG announced that the Biologics License Application (BLA) for the polyspecific immunoglobulin preparation Yimmugo (IgG Next Generation) has been accepted for review by the U.S. Food and Drug Administration (FDA) after the 60-day validation phase. With this filing notification the marketing authorization application will enter the next phase, in which the application dossier will be subjected to an in-depth substantive review. The marketing authorization application covers the indication primary immunodeficiencies (PID). After receiving approval, Biotest plans to expand the indication to include chronic primary immune thrombocytopenia (ITP). The FDA's decision on the marketing authorization application of Yimmugo is expected on June 29, 2024. Biotest's new immunoglobulin is manufactured in an innovative production process and is the main product of the new Biotest Next Level production facility. The new production facility, which uses technologies, represents Biotest's increased commitment to the global immunoglobulin market.Reported Earnings • Mar 29Full year 2022 earnings released: €0.80 loss per share (vs €1.60 loss in FY 2021)Full year 2022 results: €0.80 loss per share (improved from €1.60 loss in FY 2021). Revenue: €516.1m (flat on FY 2021). Net loss: €31.7m (loss narrowed 50% from FY 2021). Products in clinical trials Phase I: 1 Phase III: 6 Post-clinical trial products Approved (during full year): 2 Launched (during full year): 1 Revenue is forecast to grow 9.5% p.a. on average during the next 2 years, compared to a 14% growth forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has increased by 21% per year, which means it is well ahead of earnings.공시 • Feb 11Biotest AG Appoints Ainhoa Mendizabal as CFO, with Effect from 15 February, 2023Biotest AG appointed Ms. Ainhoa Mendizabal (50) to the company's Management Board as Chief Financial Officer (CFO) with effect from 15 February 2023. When Dr. Michael Ramroth was appointed Chief Executive Officer (CEO) on 1 May 2019, he initially continued to perform the duties of Chief Financial Officer in addition to his other duties. In view of the constantly growing reporting requirements, the company has now filled the position of Chief Financial Officer with Ms Mendizabal. As 'Chief Financial Officer', Ms. Mendizabal will be responsible within the Biotest Group for the areas of finance, including the treasury and tax departments, controlling, investor relations and insurance. Ms Mendizabal has worked for several years in an international consulting firm in the area of CFO Services and Enterprise Applications. From there she moved to Talecris Biotherapeutics GmbH before Talecris was acquired by Grifols S.A. Since then, Ms Mendizabal has held various executive and managerial roles in the Grifols Group in Germany and in Europe. Ms. Mendizabal holds a dual Master of Business Administration (Business Administration) in Spain and in Germany.공시 • Dec 20+ 2 more updatesBiotest Aktiengesellschaft to Report Fiscal Year 2022 Results on Mar 23, 2023Biotest Aktiengesellschaft announced that they will report fiscal year 2022 results at 12:00 PM, Central European Standard Time on Mar 23, 2023주주 수익률BIO3DGB BiotechsGB 시장7D0%1.4%2.5%1Yn/a26.9%19.4%전체 주주 수익률 보기수익률 대 산업: BIO3D의 UK Biotechs 산업 대비 성과를 판단하기에 데이터가 부족합니다.수익률 대 시장: BIO3D의 UK 시장 대비 성과를 판단하기에 데이터가 부족합니다.주가 변동성Is BIO3D's price volatile compared to industry and market?BIO3D volatilityBIO3D Average Weekly Movementn/aBiotechs Industry Average Movement9.4%Market Average Movement5.7%10% most volatile stocks in GB Market12.0%10% least volatile stocks in GB Market3.0%안정적인 주가: BIO3D는 지난 3개월 동안 UK 시장에 비해 주가 변동성이 크지 않았습니다.시간에 따른 변동성: Insufficient data to determine BIO3D의 변동성 변화를 판단할 수 없습니다.회사 소개설립직원 수CEO웹사이트19462,228Michael Ramrothwww.biotest.com더 보기Biotest Aktiengesellschaft 기초 지표 요약Biotest의 순이익과 매출은 시가총액과 어떻게 비교됩니까?BIO3D 기초 통계시가총액€1.46b순이익 (TTM)-€47.20m매출 (TTM)€517.40m2.4x주가매출비율(P/S)-26.3x주가수익비율(P/E)BIO3D는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표BIO3D 손익계산서 (TTM)매출€517.40m매출원가€394.00m총이익€123.40m기타 비용€170.60m순이익-€47.20m최근 보고된 실적Mar 31, 2023다음 실적 발표일Aug 10, 2023주당순이익(EPS)-1.19총이익률23.85%순이익률-9.12%부채/자본 비율185.4%BIO3D의 장기 실적은 어땠습니까?과거 실적 및 비교 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2023/06/26 19:18종가2023/03/29 00:00수익2023/03/31연간 수익2022/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Biotest GmbH & Co. KGaA는 3명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Torben TeichlerHauck Aufhäuser Investment BankingJan KeppelerHSBCKlaus SchloteSolventis Wertpapierhandelsbank GmbH
공시 • May 23Biotest Aktiengesellschaft announces Annual dividend, payable on July 07, 2025Biotest Aktiengesellschaft announced Annual dividend of EUR 0.0400 per share payable on July 07, 2025, ex-date on July 03, 2025 and record date on July 04, 2025.
공시 • May 22Biotest Aktiengesellschaft, Annual General Meeting, Jul 02, 2025Biotest Aktiengesellschaft, Annual General Meeting, Jul 02, 2025, at 10:30 W. Europe Standard Time.
공시 • Apr 02Grifols Biotest Holdings GmbH, proposed to acquire remaining 28.31% stake in Biotest Aktiengesellschaft (XTRA:BIO3) from shareholders for approximately €340 million.Grifols Biotest Holdings GmbH, proposed to acquire remaining 28.31% stake in Biotest Aktiengesellschaft (XTRA:BIO3) from shareholders for approximately €340 million on March 31, 2025. The Management Board and the Supervisory Board will carefully review the offer document for the public delisting acquisition offer and issue a joint reasoned statement in accordance with Section 27 of the German Securities Acquisition and Takeover Act. The delisting agreement contains provisions that Grifols, S.A. intends to support Biotest AG in an economically reasonable manner. After the revocation of the stock exchange admission becomes effective, the shares of Biotest AG will no longer be admitted to trading on a domestic regulated market or a comparable market abroad. According to the provisions of the delisting agreement, Grifols Biotest Holdings GmbH, a 100% subsidiary of Grifols, S.A., will make an unconditional public delisting acquisition offer to the shareholders of Biotest AG to acquire all ordinary and preference shares of Biotest AG that are not already held by Grifols Biotest Holdings GmbH, in exchange for a cash consideration of €43.00 per Biotest ordinary share and €30.00 per Biotest preference share, subject to adjustments due to legal provisions. The terms and conditions of the delisting offer will be communicated in the offer document ("Offer Document") to be prepared by Grifols and to be examined by the German federal financial supervisory. Banco Santander, S.A. acted as a financial advisor to Biotest Aktiengesellschaft.
공시 • Mar 18+ 1 more updateBiotest Aktiengesellschaft to Report Q3, 2025 Results on Nov 10, 2025Biotest Aktiengesellschaft announced that they will report Q3, 2025 results on Nov 10, 2025
공시 • Mar 07Martin Möller to Leave as Chief Financial Officer of Biotest AG on 15 March 2025The Board of Management of Biotest AG announced that Chief Financial Officer Martin Möller will terminate his position as CFO as planned at the end of his contract expires on 15 March 2025. The Supervisory Board has already initiated the search for a suitable successor and aims to fill the position in the near future. Martin Möller will continue to support Biotest AG in an advisory capacity beyond the end of his contract.
공시 • Jan 09Important milestone for Biotest: Biologics License Application for Fibrinogen submitted to the US Food and Drug Administration (FDA)Biotest AG announced that the Biologics License Application (BLA) for Biotest’s Fibrinogen has been submitted to the US Food and Drug Administration. Fibrinogen is the second product developed and manufactured by Biotest in Dreieich, Germany, for which a BLA has been submitted to the FDA. The new application covers both supplementation in patients with acquired fibrinogen deficiency and treatment and prophylaxis of acute bleeding episodes in all patients with congenital fibrinogen deficiency. The application is now under evaluation by the FDA, with a decision anticipated by the end of 2025. This submission follows Biotest’s earlier application for marketing authorization in selected European markets filed in October 2024. In many regions of the world, the use of cryoprecipitate or fresh frozen plasma as a fibrinogen substitute is the standard of care for the management of major surgical bleeding. However, these treatments contain not only fibrinogen, but also additional proteins and components that may exhibit undesired effects for the patient. In addition, they are not subject to the same rigorous pathogen safety protocols as Fibrinogen. Fibrinogen also offers the significant advantages of being readily available and allowing for faster administration, ensuring timely and targeted treatment.
공시 • May 23Biotest Aktiengesellschaft announces Annual dividend, payable on July 07, 2025Biotest Aktiengesellschaft announced Annual dividend of EUR 0.0400 per share payable on July 07, 2025, ex-date on July 03, 2025 and record date on July 04, 2025.
공시 • May 22Biotest Aktiengesellschaft, Annual General Meeting, Jul 02, 2025Biotest Aktiengesellschaft, Annual General Meeting, Jul 02, 2025, at 10:30 W. Europe Standard Time.
공시 • Apr 02Grifols Biotest Holdings GmbH, proposed to acquire remaining 28.31% stake in Biotest Aktiengesellschaft (XTRA:BIO3) from shareholders for approximately €340 million.Grifols Biotest Holdings GmbH, proposed to acquire remaining 28.31% stake in Biotest Aktiengesellschaft (XTRA:BIO3) from shareholders for approximately €340 million on March 31, 2025. The Management Board and the Supervisory Board will carefully review the offer document for the public delisting acquisition offer and issue a joint reasoned statement in accordance with Section 27 of the German Securities Acquisition and Takeover Act. The delisting agreement contains provisions that Grifols, S.A. intends to support Biotest AG in an economically reasonable manner. After the revocation of the stock exchange admission becomes effective, the shares of Biotest AG will no longer be admitted to trading on a domestic regulated market or a comparable market abroad. According to the provisions of the delisting agreement, Grifols Biotest Holdings GmbH, a 100% subsidiary of Grifols, S.A., will make an unconditional public delisting acquisition offer to the shareholders of Biotest AG to acquire all ordinary and preference shares of Biotest AG that are not already held by Grifols Biotest Holdings GmbH, in exchange for a cash consideration of €43.00 per Biotest ordinary share and €30.00 per Biotest preference share, subject to adjustments due to legal provisions. The terms and conditions of the delisting offer will be communicated in the offer document ("Offer Document") to be prepared by Grifols and to be examined by the German federal financial supervisory. Banco Santander, S.A. acted as a financial advisor to Biotest Aktiengesellschaft.
공시 • Mar 18+ 1 more updateBiotest Aktiengesellschaft to Report Q3, 2025 Results on Nov 10, 2025Biotest Aktiengesellschaft announced that they will report Q3, 2025 results on Nov 10, 2025
공시 • Mar 07Martin Möller to Leave as Chief Financial Officer of Biotest AG on 15 March 2025The Board of Management of Biotest AG announced that Chief Financial Officer Martin Möller will terminate his position as CFO as planned at the end of his contract expires on 15 March 2025. The Supervisory Board has already initiated the search for a suitable successor and aims to fill the position in the near future. Martin Möller will continue to support Biotest AG in an advisory capacity beyond the end of his contract.
공시 • Jan 09Important milestone for Biotest: Biologics License Application for Fibrinogen submitted to the US Food and Drug Administration (FDA)Biotest AG announced that the Biologics License Application (BLA) for Biotest’s Fibrinogen has been submitted to the US Food and Drug Administration. Fibrinogen is the second product developed and manufactured by Biotest in Dreieich, Germany, for which a BLA has been submitted to the FDA. The new application covers both supplementation in patients with acquired fibrinogen deficiency and treatment and prophylaxis of acute bleeding episodes in all patients with congenital fibrinogen deficiency. The application is now under evaluation by the FDA, with a decision anticipated by the end of 2025. This submission follows Biotest’s earlier application for marketing authorization in selected European markets filed in October 2024. In many regions of the world, the use of cryoprecipitate or fresh frozen plasma as a fibrinogen substitute is the standard of care for the management of major surgical bleeding. However, these treatments contain not only fibrinogen, but also additional proteins and components that may exhibit undesired effects for the patient. In addition, they are not subject to the same rigorous pathogen safety protocols as Fibrinogen. Fibrinogen also offers the significant advantages of being readily available and allowing for faster administration, ensuring timely and targeted treatment.
공시 • Nov 15Biotest Aktiengesellschaft to Report Fiscal Year 2024 Results on Mar 28, 2025Biotest Aktiengesellschaft announced that they will report fiscal year 2024 results on Mar 28, 2025
공시 • Jul 29Biotest Aktiengesellschaft to Report Q2, 2024 Results on Aug 06, 2024Biotest Aktiengesellschaft announced that they will report Q2, 2024 results on Aug 06, 2024
공시 • Jun 18Biotest Receives FDA Approval for Innovative Yimmugo Immunoglobulin to Treat Primary ImmunodeficienciesGrifols announced that Biotest, a Grifols Group company, has received approval from the United States Food and Drug Administration (FDA) for Yimmugo®, an innovative intravenous immunoglobulin (Ig) therapeutic, to treat primary immunodeficiencies (PID). Yimmugo, developed by Biotest, adds to Grifols’ strong franchise of industry-leading intravenous and subcutaneous Ig treatments at a time of growing demand for plasma-derived medicines to treat immunodeficiencies, in which a part of the body’s immune system is missing or does not function properly, and other medical conditions. The first U.S.-approved medicine in Biotest’s portfolio, Yimmugo is produced using a state-of-the-art process at Biotest’s new FDA-certified “Next Level” production facility in Dreieich, Germany, which is already approved for production and marketing in Europe. The launch of Yimmugo in the U.S. in the second part of 2024 follows its successful introduction in Europe at the end of 2022 and is poised to add to Grifols' future revenue growth and profitability. Yimmugo is the first of a threesome of Biotest plasma proteins on the horizon destined for markets including the U.S. The other two, both in late-stage development, are a fibrinogen concentrate (FC) to treat acquired fibrinogen deficiency – it would be the first FC approved for this indication in the U.S. – and trimodulin, a polyvalent Ig to treat community-acquired pneumonia (CAP) or severe community-acquired pneumonia (sCAP). The strategic acquisition of Biotest and the integration of its specialized resources has significantly accelerated Grifols innovation, deepened its product pipeline and furthered its industry leadership. Yimmugo is a newly developed polyvalent immunoglobulin G preparation from human blood plasma for intravenous administration (IVIg). The sugar-free ready-to-use solution is approved in the US for substitution therapy in primary antibody deficiency syndromes. Yimmugo is the first approved product from the new Biotest Next Level production facility. The modern production process stands for the highest product quality and an extremely responsible use of resources. Important Safety Information: Thrombosis may occur with immune globulin intravenous (IGIV) products, including YIMMUGO. Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur with the administration of IGIV products in predisposed patients. Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. YIMMUGO does not contain sucrose. For patients at risk of thrombosis, renal dysfunction or renal failure, administer YIMMUGO at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.
공시 • Mar 29Biotest Aktiengesellschaft, Annual General Meeting, May 07, 2024Biotest Aktiengesellschaft, Annual General Meeting, May 07, 2024, at 10:30 Central European Standard Time. Location: Alte Oper Frankfurt, Mozart Saal, Opernplatz, Franfurt Am Main Germany Agenda: To consider the adopted annual financial statements of Biotest AG and the approved consolidated financial statements as at 31 December 2023; to consider the Resolution on the discharge of the members of the Management Board for the financial year 2023; to consider Resolution on the discharge of the members of the Supervisory Board for the financial year 2023; to consider the Election of the auditor for the financial year 2024; and to consider the other business matters.
공시 • Jan 23+ 2 more updatesBiotest Aktiengesellschaft to Report First Half, 2024 Results on Jul 30, 2024Biotest Aktiengesellschaft announced that they will report first half, 2024 results on Jul 30, 2024
공시 • Nov 03Biotest Aktiengesellschaft to Report Fiscal Year 2023 Results on Mar 28, 2024Biotest Aktiengesellschaft announced that they will report fiscal year 2023 results on Mar 28, 2024
공시 • Oct 07Biotest Aktiengesellschaft Raises Earnings Guidance for the Year 2023Biotest Aktiengesellschaft raised earnings guidance for the year 2023. Biotest AG had forecasted in April 2023 an EBIT that may possibly exceed EUR 100 million. Based on current information, the Executive Board expects EBIT for fiscal 2023 to be in the order of EUR 130 - 170 million. The Executive Board continues to aim for a mid-single-digit percentage increase in revenue for the 2023 financial year compared to 2022, excluding revenue from the technology transfer and licensing agreement.
공시 • Oct 06Biotest AG Appoints Peter Janssen as Chairman of the Management Board, Effective from January 1, 2024Biotest AG at its meeting held on October 5, 2023 appointed Mr. Peter Janssen (57) as Chairman of the Management Board of Biotest AG with effect from 1 January 2024. He will take over the chairmanship of the Board of Management from Dr Michael Ramroth (62), who held this position for three and a half years and is retiring as planned for reasons of age. Peter Janssen has been a member of the Management Board of Biotest AG since 2022 and heads the Commercial and Industrial Operations divisions. Previously, he was Executive VP of Prothya Netherlands and CEO of Prothya Belgium. Mr. Janssen also worked for Pfizer for 14 years and for its animal health spin-off Zoetis for 5 years. Peter Janssen started his career as an assistant professor at the University of Leuven in Belgium, was a reserve officer in the Belgian Air Force and worked in the semiconductor division of the industrial gas company Air Products in Pennsylvania, USA. He holds a Master of Science (Dipl. Ing.) in Electromechanics, a Master in Business Administration and a Management Diploma from INSEAD in France. In addition to Peter Janssen as Chairman of the Management Board, the Management Board of Biotest AG will continue to include Ainhoa Mendizabal Zubiaga as CFO and Dr. Jörg Schüttrumpf as CSO.
공시 • Sep 13Biotest Treats First Patient with Severe Community- Acquired Pneumonia in Phase III Trial with TrimodulinBiotest announced that the first patient with sCAP has been treated in the phase III ESsCAPE trial in an intensive care unit. This multinational phase III clinical trial is expected to enrol approximately 590 adult patients with severe Community Acquired Pneumonia (sCAP). The ESsCAPE trial will be conducted in up to 20 countries worldwide and patients will receive either trimodulin or placebo as add-on therapy to standard of care. Severe CAP is a life-threatening condition. Patients must be admitted to an intensive care unit (ICU) and often receive oxygen through invasive mechanical ventilation (IMV). These patients often develop additional critical illnesses such as sepsis, septic shock, and multiple organ dysfunction or failure. Despite existing treatment options, mortality in these patients remains high. The clinical concept of this prospective, double-blind, placebo-controlled phase III trial, was developed based on the promising results of the previous phase II clinical trial (CIGMA) in 160 sCAP patients requiring IMV. In the CIGMA trial a subgroup of patients with evidence of severe inflammation showed an encouraging reduction in the mortality rate when treated with trimodulin. Biotest's development product trimodulin is a globally unique, innovative polyvalent IgM, IgA, IgG antibody composition, purified from human plasma. In addition to clinical development for sCAP, trimodulin is also currently in development for the treatment of COVID-19. Biotest's development products trimodulin is an innovative polyvalent antibody composition, purified from human Plasma. In comparison to standard IgG preparations (IVIG), trimodulin contains relevant amounts of IgM and IgA in addition to IgG. Trimodulin is currently in clinical development for the treatment of patients with severe community-acquired pneumonia (sCAP) and for patients with moderate or severe COVID-19. Research so far has shown that trimodulin could intervene with a number of mechanisms involved in pathological processes that would otherwise lead to respiratory failure, sepsis, multi-organ failure and finally to death of the patient. Due to the large variety of polyvalent antibodies present in trimodulin, the impaired immune system is supported in various ways. The antibodies bind to various types of pathogens including viruses and bacteria as well as their toxins and support their clearance by the immune system. Particularly the IgM component in trimodulin can reduce dysregulated immune responses, preventing the immune system to attack host tissues, in this case, the lung. In this way, trimodulin may prevent progression of disease, including the need for invasive mechanical ventilation and other intensive care procedures, and finally death. Severe community acquired pneumonia (sCAP) is usually defined as pneumonia acquired outside the hospital that requires intensive medical care. mortality of sCAP patients admitted to the intensive care unit is high and has not improved much in recent years.
공시 • Sep 08Biotest AG Announces US Food and Drug Administration Accepts Marketing Authorization Application for Immunoglobulin YimmugoBiotest AG announced that the Biologics License Application (BLA) for the polyspecific immunoglobulin preparation Yimmugo (IgG Next Generation) has been accepted for review by the U.S. Food and Drug Administration (FDA) after the 60-day validation phase. With this filing notification the marketing authorization application will enter the next phase, in which the application dossier will be subjected to an in-depth substantive review. The marketing authorization application covers the indication primary immunodeficiencies (PID). After receiving approval, Biotest plans to expand the indication to include chronic primary immune thrombocytopenia (ITP). The FDA's decision on the marketing authorization application of Yimmugo is expected on June 29, 2024. Biotest's new immunoglobulin is manufactured in an innovative production process and is the main product of the new Biotest Next Level production facility. The new production facility, which uses technologies, represents Biotest's increased commitment to the global immunoglobulin market.
Reported Earnings • Mar 29Full year 2022 earnings released: €0.80 loss per share (vs €1.60 loss in FY 2021)Full year 2022 results: €0.80 loss per share (improved from €1.60 loss in FY 2021). Revenue: €516.1m (flat on FY 2021). Net loss: €31.7m (loss narrowed 50% from FY 2021). Products in clinical trials Phase I: 1 Phase III: 6 Post-clinical trial products Approved (during full year): 2 Launched (during full year): 1 Revenue is forecast to grow 9.5% p.a. on average during the next 2 years, compared to a 14% growth forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has increased by 21% per year, which means it is well ahead of earnings.
공시 • Feb 11Biotest AG Appoints Ainhoa Mendizabal as CFO, with Effect from 15 February, 2023Biotest AG appointed Ms. Ainhoa Mendizabal (50) to the company's Management Board as Chief Financial Officer (CFO) with effect from 15 February 2023. When Dr. Michael Ramroth was appointed Chief Executive Officer (CEO) on 1 May 2019, he initially continued to perform the duties of Chief Financial Officer in addition to his other duties. In view of the constantly growing reporting requirements, the company has now filled the position of Chief Financial Officer with Ms Mendizabal. As 'Chief Financial Officer', Ms. Mendizabal will be responsible within the Biotest Group for the areas of finance, including the treasury and tax departments, controlling, investor relations and insurance. Ms Mendizabal has worked for several years in an international consulting firm in the area of CFO Services and Enterprise Applications. From there she moved to Talecris Biotherapeutics GmbH before Talecris was acquired by Grifols S.A. Since then, Ms Mendizabal has held various executive and managerial roles in the Grifols Group in Germany and in Europe. Ms. Mendizabal holds a dual Master of Business Administration (Business Administration) in Spain and in Germany.
공시 • Dec 20+ 2 more updatesBiotest Aktiengesellschaft to Report Fiscal Year 2022 Results on Mar 23, 2023Biotest Aktiengesellschaft announced that they will report fiscal year 2022 results at 12:00 PM, Central European Standard Time on Mar 23, 2023
